Skip to main content
Top
Published in: Trials 1/2019

Open Access 01-12-2019 | Biomarkers | Commentary

Mind the gap? The platform trial as a working environment

Authors: Liz Morrell, Joshua Hordern, Louise Brown, Matthew R. Sydes, Claire L. Amos, Richard S. Kaplan, Mahesh K. B. Parmar, Timothy S. Maughan

Published in: Trials | Issue 1/2019

Login to get access

Abstract

Background

Trials have become bigger and more complicated due to the complexity introduced by biomarker stratification, and the advent of multi-arm multi-stage trials, and umbrella and basket platform designs. The trials unit at University College London has been at the forefront of this work, with ground-breaking trials such as STAMPEDE and FOCUS4. The trial management and data management teams on these trials have summarised the operational challenges, to enable the broader clinical trials community to learn from their experiences. In a small-scale qualitative study, we examined the personal experience of individual researchers working on these trials.

Commentary

We found reports of high workloads, with potentially significant stress for individuals and with an impact on their career choices. We conclude that there was an initial underestimation of the work required and of the inherent, largely unanticipated, challenges. We discuss the importance of fully understanding these trials’ resource requirements, both for those writing grant applications and critically, for those with responsibility for deciding on funding.
The working environment was characterised by three features: complexity, scale and heightened expectations. These features are highly attractive for professional development and engender high levels of loyalty and commitment. We observed a trade-off between these intrinsic rewards and the continuous demands of overlapping tasks, balancing a mix of routine and high-profile work, and the changing nature of pivotal roles. Such demands present challenges for colleague relationships, by enhancing the potential for competition and by disrupting the natural opportunities to pause, review and celebrate team achievements. In addition, molecular stratification in effect brings the patient into the trial office, as a specific individual, despite anonymisation, who is owed test results and a treatment decision. We discuss these observations with a view to interconnecting the need for compassion for patients with caring for the researchers engaged in the research ecosystem who are aiming to produce much hoped-for advances in medical science.

Conclusions

There is a need for increased awareness of the challenge these studies place on those throughout the team delivering the study. Such considerations must influence leaders and funders, both in their initial budget considerations and throughout delivery.
Literature
1.
go back to reference Parmar MK, Sydes MR, Cafferty FH, Choodari-Oskooei B, Langley RE, Brown L, et al. Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. Clinical Trials. 2017;14(5):451–61.CrossRef Parmar MK, Sydes MR, Cafferty FH, Choodari-Oskooei B, Langley RE, Brown L, et al. Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. Clinical Trials. 2017;14(5):451–61.CrossRef
2.
go back to reference Parmar MKB, Carpenter J, Sydes MR. More multiarm randomised trials of superiority are needed. Lancet. 2014;384(9940):283–4.CrossRef Parmar MKB, Carpenter J, Sydes MR. More multiarm randomised trials of superiority are needed. Lancet. 2014;384(9940):283–4.CrossRef
3.
go back to reference Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med. 2017;377(1):62–70.CrossRef Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med. 2017;377(1):62–70.CrossRef
4.
go back to reference Sydes MR, Parmar MK, Mason MD, Clarke NW, Amos C, Anderson J, et al. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials. 2012;13(1):168.CrossRef Sydes MR, Parmar MK, Mason MD, Clarke NW, Amos C, Anderson J, et al. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials. 2012;13(1):168.CrossRef
5.
go back to reference Schiavone F, Bathia R, Letchemanan K, Masters L, Amos C, Bara A, et al. This is a Platform Alteration: A Trial Management Perspective on the Operational Aspects of Adaptive and Platform and Umbrella Protocols. Trials. 2019. Schiavone F, Bathia R, Letchemanan K, Masters L, Amos C, Bara A, et al. This is a Platform Alteration: A Trial Management Perspective on the Operational Aspects of Adaptive and Platform and Umbrella Protocols. Trials. 2019.
6.
go back to reference Hague D, Townsend S, Masters L, Rauchenberger M, Looy NV, Diaz-Montana C, et al. Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons. Trials. 2019. Hague D, Townsend S, Masters L, Rauchenberger M, Looy NV, Diaz-Montana C, et al. Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons. Trials. 2019.
7.
go back to reference Feiler T, Gaitskell K, Maughan T, Hordern J. Personalised Medicine: The Promise, the Hype and the Pitfalls. New Bioeth. 2017;23(1):1–12.CrossRef Feiler T, Gaitskell K, Maughan T, Hordern J. Personalised Medicine: The Promise, the Hype and the Pitfalls. New Bioeth. 2017;23(1):1–12.CrossRef
8.
go back to reference Hordern J, Maughan T, Feiler T, Morrell L, Horne R, Sullivan R. The “Molecularly Unstratified” Patient: A Focus for Moral, Psycho-Social and Societal Research. Biomed Hub. 2017;2(Suppl. 1):11. Hordern J, Maughan T, Feiler T, Morrell L, Horne R, Sullivan R. The “Molecularly Unstratified” Patient: A Focus for Moral, Psycho-Social and Societal Research. Biomed Hub. 2017;2(Suppl. 1):11.
9.
go back to reference Hordern J. Self-Knowledge and Risk in Stratified Medicine. New Bioeth. 2017;23(1):55–63.CrossRef Hordern J. Self-Knowledge and Risk in Stratified Medicine. New Bioeth. 2017;23(1):55–63.CrossRef
10.
go back to reference Tweedie J, Hordern J, Dacre J. Advancing medical professionalism. London: Royal College of Physicians; 2018. Tweedie J, Hordern J, Dacre J. Advancing medical professionalism. London: Royal College of Physicians; 2018.
11.
go back to reference Siegrist J. Adverse Health Effects of High-Effort/Low-Reward Conditions. J Occup Health Psychol. 1996;1(1):27–41.CrossRef Siegrist J. Adverse Health Effects of High-Effort/Low-Reward Conditions. J Occup Health Psychol. 1996;1(1):27–41.CrossRef
Metadata
Title
Mind the gap? The platform trial as a working environment
Authors
Liz Morrell
Joshua Hordern
Louise Brown
Matthew R. Sydes
Claire L. Amos
Richard S. Kaplan
Mahesh K. B. Parmar
Timothy S. Maughan
Publication date
01-12-2019
Publisher
BioMed Central
Keyword
Biomarkers
Published in
Trials / Issue 1/2019
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-019-3377-5

Other articles of this Issue 1/2019

Trials 1/2019 Go to the issue